FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Alnylam Gets Additional Approval for Amvuttra

[ Price : $8.95]

FDA approves an Alnylam Pharmaceuticals supplemental NDA for Amvuttra (vutrisiran), an RNAi therapeutic for treating transthyretin...

Fabhalta Approved for Rare Kidney Disease

[ Price : $8.95]

FDA approves a Novartis NDA for Fabhalta (iptacopan) for treating adults with C3 glomerulopathy to reduce proteinuria.

Abbott IDE OKd for Coronary Artery Blockages Trial

[ Price : $8.95]

FDA approves an Abbott IDE for a clinical trial to evaluate its investigational coronary intravascular lithotripsy system and its ...

New FDA Building Completed as DOGE Cuts 27 Others

[ Price : $8.95]

The government completes a construction project for a new 11,000 square feet FDA annex building in San Juan District as the Trump ...

No Panel Review for Tonix Pharma Fibromyalgia NDA

[ Price : $8.95]

FDA passes on holding an advisory committee meeting to review a Tonix Pharmaceuticals NDA for TNX-102 SL (cyclobenzaprine HCl subl...

Fast Track for Secretome Heart Failure Drug

[ Price : $8.95]

FDA awards Secretome Therapeutics a fast track designation for STM-01, the companys neonatal cardiac progenitor cell therapy for ...

FDA Clears Tenon Medical Expanded Use

[ Price : $8.95]

FDA clears a Tenon Medical 510(k) for an expanded indication for the Catamaran SI Joint Fusion System for use in augmenting thorac...

Bard Recalls Rotarex Atherectomy Device Instructions

[ Price : $8.95]

Bard Peripheral Vascular updates the instructions for use (Class 1 recall) for its Rotarex Atherectomy Systems after receiving rep...

FDA Again Delays Non-Rx Drug Final Rule

[ Price : $8.95]

FDA delays again a final rule entitled Nonprescription Drug Product With an Additional Condition for Nonprescription Use (ACNU) to...

Liver Cancer Combo Gets 2nd Complete Response Letter

[ Price : $8.95]

HLB and Chinas Antengene say FDA has issued a second complete response letter on rivoceranib and its use in combination with camre...